Sharon Mates - Intracellular Co-Founder, Chairman, CEO and Pres
ITCI Stock | USD 76.69 3.15 3.95% |
Chairman
Dr. Sharon Mates Ph.D. is the Chairman of the Board, President, Chief Executive Officer of IntraCellular Therapies, Inc. Dr. Mates was Chairman, President and Chief Executive Officer of the Company since the Merger in August 2013 and was the Chairman of the board of directors, President and Chief Executive Officer of ITI since June 2002. Dr. Mates cofounded ITI in May 2002. Prior to cofounding ITI, Dr. Mates was a cofounder of Functional Genetics, and served as its Chairman and Chief Executive Officer from December 2000 until August 2003. From 1989 to 1998, Dr. Mates was the President and a board member of North American Vaccine Inc. and its predecessor companies. Dr. Mates serves on the board of the Biotechnology Innovation Organization, emerging companies section. Dr. Mates has also served on the Advisory Council of the Center for Society and Health at the Harvard School of Public Health, the Board of Visitors of the Biotechnology Institute of the University of Maryland and the board of directors of Gildas Club of New York. Earlier in her career, Dr. Mates spent several years as a research analyst and investment banker, and as an advisor to the life sciences industry since 2014.
Age | 71 |
Tenure | 10 years |
Professional Marks | Ph.D |
Address | 430 East 29th Street, New York, NY, United States, 10016 |
Phone | 646 440 9333 |
Web | https://www.intracellulartherapies.com |
Latest Insider Transactions
Mates received her B.S. from the Ohio State University and her Ph.D. from the University of Washington, and completed her postdoctoral fellowships at The Massachusetts General Hospital and Harvard Medical School.Intracellular Management Efficiency
The company has return on total asset (ROA) of (0.1343) % which means that it has lost $0.1343 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2239) %, meaning that it created substantial loss on money invested by shareholders. Intracellular's management efficiency ratios could be used to measure how well Intracellular manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.2. The current Return On Capital Employed is estimated to decrease to -0.28. As of now, Intracellular's Non Currrent Assets Other are increasing as compared to previous years. The Intracellular's current Deferred Long Term Asset Charges is estimated to increase to about 635.1 K, while Total Assets are projected to decrease to under 410.9 M.Similar Executives
Found 4 records | CHAIRMAN Age | ||
William Rastetter | Neurocrine Biosciences | 69 | |
McCord Christensen | PetIQ Inc | 52 | |
Zsolt Harsanyi | Emergent Biosolutions | 76 | |
Fuad ElHibri | Emergent Biosolutions | 62 |
Management Performance
Return On Equity | -0.22 | ||||
Return On Asset | -0.13 |
Intracellular Th Leadership Team
Elected by the shareholders, the Intracellular's board of directors comprises two types of representatives: Intracellular inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Intracellular. The board's role is to monitor Intracellular's management team and ensure that shareholders' interests are well served. Intracellular's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Intracellular's outside directors are responsible for providing unbiased perspectives on the board's policies.
Lawrence Wennogle, Vice President of Drug Discovery | ||
Suresh Durgam, Senior Vice President Late Stage Clinical Development and Medical Affairs | ||
Michael Rawlins, Director | ||
Robert Nostrand, Independent Director | ||
Richard Lerner, Director | ||
Allen Fienberg, Co-Founder and VP of Bus. Devel. | ||
Suresh MD, Executive Officer | ||
Willie MD, Senior Development | ||
Lawrence CPA, CFO, Finance | ||
Kimberly Vanover, VP of Clinical Devel. | ||
Michael Olchaskey, Senior Vice President Head of Regulatory Affairs | ||
CPA CPA, CFO, Fin | ||
Christopher Alafi, Director | ||
Robert Davis, Senior Vice President and Chief Scientific Officer | ||
Mark Neumann, Executive Vice President Chief Commercial Officer | ||
Karen Esq, Senior Officer | ||
Michael Halstead, Sr. VP, General Counsel and Secretary | ||
Sharon Mates, Co-Founder, Chairman, CEO and Pres | ||
Andrew Satlin, Executive Vice President and Chief Medical Officer | ||
Michael JD, General VP | ||
Juan Sanchez, Vice President - Corporate Communications and Investor Relations | ||
Rory Riggs, Independent Director | ||
John Bardi, Senior Vice President - Market Access, Policy and Government Affairs | ||
Joel Marcus, Director | ||
Lawrence Hineline, Vice President and CFO |
Intracellular Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Intracellular a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -0.22 | ||||
Return On Asset | -0.13 | ||||
Profit Margin | (0.30) % | ||||
Operating Margin | (0.26) % | ||||
Current Valuation | 7.25 B | ||||
Shares Outstanding | 96.81 M | ||||
Shares Owned By Insiders | 2.51 % | ||||
Shares Owned By Institutions | 99.05 % | ||||
Number Of Shares Shorted | 3.47 M | ||||
Price To Earning | (6.56) X |
Intracellular Investors Sentiment
The influence of Intracellular's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Intracellular. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Intracellular's public news can be used to forecast risks associated with an investment in Intracellular. The trend in average sentiment can be used to explain how an investor holding Intracellular can time the market purely based on public headlines and social activities around Intracellular Th. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Intracellular's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Intracellular's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Intracellular's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Intracellular.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Intracellular in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Intracellular's short interest history, or implied volatility extrapolated from Intracellular options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Intracellular Th. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. Note that the Intracellular Th information on this page should be used as a complementary analysis to other Intracellular's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Complementary Tools for Intracellular Stock analysis
When running Intracellular's price analysis, check to measure Intracellular's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intracellular is operating at the current time. Most of Intracellular's value examination focuses on studying past and present price action to predict the probability of Intracellular's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Intracellular's price. Additionally, you may evaluate how the addition of Intracellular to your portfolios can decrease your overall portfolio volatility.
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
FinTech Suite Use AI to screen and filter profitable investment opportunities |
Is Intracellular's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intracellular. If investors know Intracellular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Intracellular listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.46) | Revenue Per Share 4.843 | Quarterly Revenue Growth 0.503 | Return On Assets (0.13) | Return On Equity (0.22) |
The market value of Intracellular Th is measured differently than its book value, which is the value of Intracellular that is recorded on the company's balance sheet. Investors also form their own opinion of Intracellular's value that differs from its market value or its book value, called intrinsic value, which is Intracellular's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intracellular's market value can be influenced by many factors that don't directly affect Intracellular's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Intracellular's value and its price as these two are different measures arrived at by different means. Investors typically determine if Intracellular is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Intracellular's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.